Taxol-based Brug-eluting Stents as an Alternative to Traditional Stenting for Coronary Atherosclerotic Heart Disease (CAD)

Please note: All assessments are current as of the review date; however, new evidence that may have been published subsequently is not considered.
Review Date:	June 9, 2004
Recommendation:	This topic was reviewed on June 9, 2004. TAXUS paclitaxel-eluting stents for de novo native coronary lesions for patients with angina pectoris or silent ischemia and greater than 50 percent de novo stenosis of 10 mm-28 mm in length, or one or more native coronary arteries with a diameter ≥2.5 mm and ≤ 3.75 mm meet CTAF technology assessment criteria. TAXUS paclitaxel-eluting stents for treatment of stenotic lesions of the left main coronary artery; for treatment of stenotic lesions of non-coronary arteries such as saphenous vein grafts; for in-stent restenosis; for treatment of non-atherosclerotic anatomies (i.e. thrombotic lesions associated with acute MI); for bifurcation lesions; or for prior brachytherapy; and other paclitaxel drug-eluting stents do not meet CTAF technology assessment criteria for safety, effectiveness and improvement in health outcomes.
Decision:	Partially Meets CTAF Criteria
Full Assessment:	Download (PDF)

Search Assessments